The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Histopathologic features after neoadjuvant chemotherapy (NACT) and immunotherapy impact patient outcomes. Extensive inflammation predicts better survival, while residual tumor increases progression risk.
Area Of Science
- Oncology
- Pathology
- Immunotherapy
Background
- Histopathologic features post-neoadjuvant chemotherapy (NACT) can correlate with patient outcomes.
- Assessing these features after combined immunotherapy and NACT/bevacizumab is crucial for understanding treatment efficacy.
Purpose Of The Study
- To evaluate histopathologic characteristics following NACT/bevacizumab plus atezolizumab or placebo.
- To correlate these features with clinical outcomes, including progression-free survival (PFS) and overall survival (OS).
Main Methods
- Central histopathologic scoring of surgical specimens from the IMagyn050/GOG3015/ENGOT-ov39 trial.
- Analysis of tissue from interval cytoreductive surgery (ICS) after NACT/bevacizumab and immunotherapy.
- Correlation of histopathologic findings (residual tumor, necrosis, fibrosis, inflammation) with clinical outcomes.
Main Results
- No significant differences in PFS or OS were observed between the atezolizumab and placebo arms.
- Multivariate analyses indicated that residual tumor increased the risk of progression.
- Extensive inflammation was associated with a decreased risk of death and a greater likelihood of response to NACT/bevacizumab plus immunotherapy.
Conclusions
- Histopathologic assessment of ICS specimens can provide insights into clinical outcomes.
- Inflammation and residual tumor are key features that may predict treatment response and survival.
- Further research using advanced tools is warranted to deepen the understanding of these correlations.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.